# EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

Study · id `cardio:ct-nct01069003` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01069003](<https://clinicaltrials.gov/study/NCT01069003>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01069003

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2272 participants.

## Technical summary

Registry record NCT01069003. Randomized; triple masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2016-01-20.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2272 participants (enrolled count; ClinicalTrials.gov record NCT01069003, source copy `cardio:ctgov-nct01069003-2016-01-20`, retrieved 2026-10-26)
- Start date: 2010-04 (registry gives no type) (ClinicalTrials.gov record NCT01069003, source copy `cardio:ctgov-nct01069003-2016-01-20`, retrieved 2026-10-26)
- Primary completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01069003, source copy `cardio:ctgov-nct01069003-2016-01-20`, retrieved 2026-10-26)
- Completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01069003, source copy `cardio:ctgov-nct01069003-2016-01-20`, retrieved 2026-10-26)
- Results first posted: 2016-01-20 (ClinicalTrials.gov record NCT01069003, source copy `cardio:ctgov-nct01069003-2016-01-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01069003, source copy `cardio:ctgov-nct01069003-2016-01-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01069003-2016-01-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
- Acronym: EDUCATE
- Condition: Coronary Artery Disease
- Intervention (Drug): Placebo Arm
- Intervention (Drug): Thienopyridine Therapy
- Intervention (Device): Surveillance Arm
- Lead sponsor: Medtronic Vascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Medtronic Vascular (`cardio:org-medtronic-vascular`)

## Provenance

Content hash: 46c66d7ccdbed1bbf34a6c87cfd965f5df37e8591bd2144c29b02a96fce49f8f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
